May 10
|
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
|
May 10
|
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
May 9
|
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
|
May 9
|
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
|
May 3
|
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
|
May 2
|
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
Apr 25
|
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
|
Apr 23
|
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
|
Apr 19
|
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
Apr 4
|
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
|
Apr 4
|
How Adverum (ADVM) Stock Stands Out in a Strong Industry
|
Apr 3
|
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
|
Mar 27
|
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
Mar 20
|
Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments
|
Mar 19
|
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
|
Mar 18
|
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
|
Feb 8
|
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
|
Feb 5
|
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
|
Jan 29
|
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
|
Jan 4
|
Here's Why You Should Invest in Adverum (ADVM) Stock Now
|